Esperion Therapeutics Q3 2024 Earnings Report $1.82 -0.03 (-1.35%) As of 02/21/2025 03:59 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Earnings HistoryForecast Esperion Therapeutics EPS ResultsActual EPS-$0.15Consensus EPS -$0.14Beat/MissMissed by -$0.01One Year Ago EPS-$0.37Esperion Therapeutics Revenue ResultsActual Revenue$51.63 millionExpected Revenue$55.44 millionBeat/MissMissed by -$3.81 millionYoY Revenue GrowthN/AEsperion Therapeutics Announcement DetailsQuarterQ3 2024Date11/7/2024TimeBefore Market OpensESPR Upcoming EarningsEsperion Therapeutics will be holding an earnings conference call on Tuesday, March 4 at 8:00 AM Eastern. Interested parties can register for or listen to the call. Conference Call ResourcesConference CallSlide DeckPress ReleaseESPR Earnings HistorySlide DeckFull Screen Slide DeckPowered by Esperion Therapeutics Earnings HeadlinesEsperion to Report Fourth Quarter and Full Year 2024 Financial Results on March 4February 18, 2025 | globenewswire.comZacks Research Issues Negative Outlook for ESPR EarningsFebruary 18, 2025 | americanbankingnews.comEx-CIA Advisor: Trump 2.0 Could “Send Gold to $10,000”Experts forecast gold's price racing to $4,000… and an ex-CIA advisor predicts we'll see gold hit $10,000. Should you sit on the sideline while this is happening?February 22, 2025 | Colonial Metals (Ad)Esperion Therapeutics (NASDAQ:ESPR) Given Market Outperform Rating at JMP SecuritiesFebruary 14, 2025 | americanbankingnews.comEsperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)February 13, 2025 | globenewswire.comEsperion price target lowered to $4 from $7 at JMP SecuritiesFebruary 11, 2025 | markets.businessinsider.comSee More Esperion Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Esperion Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Esperion Therapeutics and other key companies, straight to your email. Email Address About Esperion TherapeuticsEsperion Therapeutics (NASDAQ:ESPR), a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.View Esperion Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Hims & Hers Earnings Could Be a Game Changer—What to Do NowAnalysts See Buying Opportunity in NVIDIA Before EarningsAirbnb's Earnings: Sky High Results, Grounded Guidance?Is Coinbase Stock a Buy After Earnings?CVS Health: Earnings Beat Ignites Stock RallyQualcomm’s Post-Earnings Dip: A Prime Buying Opportunity?Cirrus Logic Upgraded After Q3 Earnings Beat—More Gains Ahead? Upcoming Earnings Workday (2/24/2025)Intuit (2/25/2025)American Tower (2/25/2025)Bank of Montreal (2/25/2025)Bank of Nova Scotia (2/25/2025)Public Storage (2/25/2025)NVIDIA (2/26/2025)Synopsys (2/26/2025)Salesforce (2/26/2025)Lowe's Companies (2/26/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
